VANCOUVER, British Columbia, March 6, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has signed a letter of intent with Crudessence Kombucha Inc. ("RISE") to acquire the worldwide exclusive license "the License" to produce, distribute, market and sell a Kombucha tea infused or blended with additional nutraceutical and bioceutical formulas developed and owned by Abattis and its subsidiaries. Under the Terms of the Agreement will acquire "the License" in exchange for 500,000 shares of Abattis at a deemed price of CAD $0.20 and a running technology royalty fee to "RISE".

Rise Kombucha is a highly successful brand sold across Canada, the purpose of the LOI is to enable Abattis to initially bring a new brand of Cannabidiol CBD infused probiotic functional beverages to the markets starting in Washington and Colorado, the brand will be launched as "Cannabucha Sun Rise" this product will be the first of its kind with infused Cannabidiol "CBD" with the probiotic effects to create one of the best possible health drinks in the world. Kombucha is a microbial culture of various bacteria and yeast species. Fermentation of the culture in naturally sweetened tea produces numerous organic acids such as ascetic acid, gluconic acid, malic acid, amino acids and enzymes, and polyphenols (e.g. catechins) that improve overall health.

Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are very excited to enter into the emerging US CBD infused product markets, leading with a Kombucha beverage which is fast growing in popularity. Kombucha is a perfect delivery beverage for CBD's because it is a functional probiotic drink that strengthens the immune system, balances intestinal flora, stimulates digestion, combats stress, and increases energy."  Mr. Withrow went on to say, "With Mr. Tim Fealey, former Executive VP of Product Development for The Coca Cola Company and as our VP of Product Development we are able to ensure we achieve all of the necessary goals to make this a huge success in the markets we address."

About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

About Crudessence and Rise Kombucha.

RISE is a young rapidly growing company committed to offering living, sparkling tea beverages. In harmony with nature, our kombucha not only tastes good but also is the perfect adjunct to good health. RISE is a brand that is in sync with the evolution of society. By combining the best in natural health and the best scientific research available, we offer a delicious, healthy and affordable whole food beverage.

ON BEHALF OF THE BOARD

"Michael Withrow"                                                                        
Michael Withrow, President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

 

Contact: Nick Brusatore, +1-604-356-0411, nbrusatore@gmail.com

SOURCE Abattis Bioceuticals Corp.

Copyright 2013 PR Newswire

Abattis Bioceuticals (CE) (USOTC:ATTBF)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Abattis Bioceuticals (CE) 차트를 더 보려면 여기를 클릭.
Abattis Bioceuticals (CE) (USOTC:ATTBF)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Abattis Bioceuticals (CE) 차트를 더 보려면 여기를 클릭.